Echinacea purpurea aerial extract alters course of influenza infection in mice

Vaccine

Volumn 28, Issue 23, 2010, Pages 3956-3962

  Fusco, Dahlene ^a   Liu, Xinyan ^b   Savage, Caroline ^b   Taur, Ying ^b   Xiao, Weilie ^c   Kennelly, Edward ^c   Yuan, Jianda ^b   Cassileth, Barrie ^b   Salvatore, Mirella ^a   Papanicolaou, Genovefa A ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Cytokines; Echinacea; Influenza; Mice

Indexed keywords

ECHINACEA PURPUREA EXTRACT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; POLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DRUG ISOLATION; DRUG RESPONSE; EXPERIMENTAL INFECTION; FEMALE; FLOWER; INFLUENZA A (H1N1); LUNG HOMOGENATE; MOUSE; NONHUMAN; PLANT LEAF; PLANT STEM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE; VIRUS TITRATION; WEIGHT REDUCTION;

ANIMALS; BODY WEIGHT; CYTOKINES; ECHINACEA; FEMALE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INTERLEUKIN-10; LUNG; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; PHYTOTHERAPY; PLANT COMPONENTS, AERIAL; PLANT EXTRACTS; POLYSACCHARIDES; VIRAL LOAD;

EID: 77952422312     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.03.047     Document Type: Article

References (23)

1. Garten R., Davis C., Russell C., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A (H1N1) influenza viruses circulating in humans. Science 325 (2009) 197-201
2. Puthavathana P., Sangsiriwut K., Korkusol A., Pooruk P., Auewarakul P., Pittayawanganon C., et al. Avian influenza virus (H5N1) in human, Laos. Emerg Infect Dis 15 (2009) 127-129
3. Centers for Disease Control and Prevention (CDC). Update: influenza activity-United States, September 28, 2008-January 31, 2009. MMWR 58 (2009) 115
4. Bardia A., Nisly N.L., Zimmerman M.B., Gryzlak B., and Wallace R.B. Use of herbs among adults based on evidence-based indications: findings from the National Health Interview Survey. Mayo Clin Proc 82 (2007) 561-566
5. Woelkart, and Bauer. The role of alkamides as an active principle of echinacea. Planta Med 73 (2007) 615-623
6. Barnes J., Anderson L.A., Gibbons S., and Phillipson J.D. Echinacea species (E. angustifolia, E. pallida, E. purpurea): a review of their chemistry, pharmacology, and clinical properties. J Pharm Pharmacol 57 (2005) 929-954
7. Senchina D., Wu L., Flinn G., Konopka del N., McCoy J.A., Widrlechner M.P., et al. Year and a half old, dried Echinacea roots retain cytokine modulating capabilities in an in vitro human older adult model of influenza vaccination. Planta Med 72 (2006) 1207-1215
8. Ragupathi G., Yeung K., Leung P., Lee M., Lau C.B., Vickers A., et al. Evaluation of widely consumed botanicals as immunological adjuvants. Vaccine 26 (2008) 4860-4865
9. Pleschka S., Stein M., Schoop R., and Hudson J. Anti-viral properties and mode of action of standardized Echinacea purpurea extract against highly pathogenic avian Influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV). Virol J 6 (2009) 197
10. Tobita K., Suguira A., Enomote C., and Furuyama M. Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med Microbiol Immunol 162 (1975) 9-14
11. Brown D., Roman E., and Swain S. CD4 T cell responses to influenza infection. Semin Immunol 16 (2004) 171-177
12. Turner R., Bauer R., Woelkart K., Hulsey T., and Gangemi J. An evaluation of Echinachea angustifolia in experimental rhinovirus infections. N Eng J Med 353 (2005) 341-348
13. Verhoeven D., Teijaro J.R., and Farber D.L. Pulse-oximetry accurately predicts lung pathology and the immune response during influenza infection. Virology 390 (2009) 150-156
14. Mendel D.B., Tai C.Y., and Escarpe P.A. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 42 (1998) 640-646
15. Szyszko E., Brokstad K., Cox R., Hovden A., Madhun A., and Haaheim L. Impact of influenza vaccine formulation with a detailed analysis of the cytokine response. Scand J Immunol 64 (2006) 467-475
16. Ho L., Denney L., Luhn K., Teoh D., Clelland C., and McMichael A. Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection. Eur J Immunol 38 (2008) 1913-1922
17. Ichinohe T., Lee H.K., Ogura Y., Flavell R., and Iwasaki A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med 206 (2009) 79-87
18. 4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection. J Exp Med 180 (1994) 1273-1282
19. McKinstry K., Strutt T., Buck A., Curtis J., Dibble J., Huston G., et al. IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol 182 (2009) 7353-7363
20. Scott M., Liu S., Shapiro R., Vodovotz Y., and Billiar T. Endotoxin uptake in mouse liver is blocked by endotoxin pretreatment through a suppressor of cytokine signaling-1-dependent mechanism. Hepatology 49 (2009) 1695-1708
21. Shahangian A., Chow E., Tian X., Kang J., Ghaffari A., Liu S., et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 119 (2009) 1910-1920
22. Sun J., Madan R., Karp C.L., and Braciale T.J. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med 15 (2009) 277-284
23. Van der Sluijs K., van Elden L., Nijhuis M., Schuurman R., Pater J., Florquin S., et al. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol 172 (2004) 7603